Unknown

Dataset Information

0

Aztreonam plus Clavulanate, Tazobactam, or Avibactam for Treatment of Infections Caused by Metallo-?-Lactamase-Producing Gram-Negative Bacteria.


ABSTRACT: Metallo-?-lactamase (MBL)-producing Gram-negative bacteria are often extremely resistant, leading to a real therapeutic dead end. Here, we evaluated the in vitro and in vivo efficacy of aztreonam in combination with ceftazidime-avibactam, ceftolozane-tazobactam, or amoxicillin-clavulanate for the treatment of infections caused by MBL-producing Enterobacteriaceae, MBL-producing Pseudomonas aeruginosa, and extremely drug-resistant Stenotrophomonas maltophilia First, we report two clinical cases, namely, a urinary tract infection caused by an NDM-5-producing Escherichia coli isolate and a pulmonary infection caused by a S. maltophilia isolate efficiently treated with the association of aztreonam-ceftazidime-avibactam and aztreonam-amoxicillin-clavulanate, respectively. Then, a total of 50 MBL-producing Enterobacteriaceae isolates, 3 MBL-producing P. aeruginosa isolates, and 5 extremely drug-resistant S. maltophilia isolates were used to test aztreonam susceptibility in combination with ceftolozane-tazobactam, ceftazidime-avibactam, or amoxicillin-clavulanate. The Etest strip superposition method was used to determine the MICs of the aztreonam/inhibitor combinations. According to CLSI breakpoints, aztreonam susceptibility was fully restored for 86%, 20%, and 50% of the MBL-producing Enterobacteriaceae isolates when combined with ceftazidime-avibactam, ceftolozane-tazobactam, and amoxicillin-clavulanate, respectively. In P. aeruginosa, the aztreonam-ceftazidime-avibactam combination was the most potent, even though the reduction in MICs was at most 2-fold. With the 5 S. maltophilia isolates, aztreonam-ceftazidime-avibactam and aztreonam-amoxicillin-clavulanate were found to be equal (100% susceptibility). Overall, aztreonam-ceftazidime-avibactam was the most potent combination to treat infections caused by MBL producers compared with aztreonam-amoxicillin-clavulanate and aztreonam-ceftolozane-tazobactam. However, in many cases aztreonam-amoxicillin-clavulanate was found to be as efficient as aztreonam-ceftazidime-avibactam, offering the main advantage to be markedly cheaper. We also confirmed the validity of Etest superpositions as a very simple method to determine MICs of aztreonam combinations.

SUBMITTER: Emeraud C 

PROVIDER: S-EPMC6496057 | biostudies-literature | 2019 May

REPOSITORIES: biostudies-literature

altmetric image

Publications

Aztreonam plus Clavulanate, Tazobactam, or Avibactam for Treatment of Infections Caused by Metallo-β-Lactamase-Producing Gram-Negative Bacteria.

Emeraud Cécile C   Escaut Lelia L   Boucly Athénaïs A   Fortineau Nicolas N   Bonnin Rémy A RA   Naas Thierry T   Dortet Laurent L  

Antimicrobial agents and chemotherapy 20190425 5


Metallo-β-lactamase (MBL)-producing Gram-negative bacteria are often extremely resistant, leading to a real therapeutic dead end. Here, we evaluated the <i>in vitro</i> and <i>in vivo</i> efficacy of aztreonam in combination with ceftazidime-avibactam, ceftolozane-tazobactam, or amoxicillin-clavulanate for the treatment of infections caused by MBL-producing <i>Enterobacteriaceae</i>, MBL-producing <i>Pseudomonas aeruginosa</i>, and extremely drug-resistant <i>Stenotrophomonas maltophilia</i> Fir  ...[more]

Similar Datasets

| S-EPMC7674043 | biostudies-literature
| S-EPMC5744226 | biostudies-literature
| S-EPMC8388901 | biostudies-literature
| S-EPMC9723239 | biostudies-literature
| PRJNA871076 | ENA
| S-EPMC6879249 | biostudies-literature
| S-EPMC10988999 | biostudies-literature
| S-EPMC9865866 | biostudies-literature
| S-EPMC2738676 | biostudies-literature